Professor and CLEARbridge Chair in Cancer Immunotherapy, University of Sydney
BIOGRAPHY
OCT 15, 2025 5:30 AM PDT
Phase 1 studies of CD19 CAR-T cell immunotherapy for large B cell lymphoma.
Presented at:
Cell & Gene Therapy Virtual Event Series 2025
Abstract
Lymphodepletion chemotherapy followed by infusion of T cells that are genetically modified to express a chimeric antigen receptor (CAR) targeted to CD19 is a novel therapy for patients with relapsed and/or refractory B cell malignancies.We conducted a series of phase 1/2 clinical trials in which CD19 CAR-T cells are manufactured from distinct subsets of T cells and formulated in a defined composition for infusion to patients with large B cell non-Hodgkin lymphoma. Outcomes of these studies and correlative research will be presented.
Learning Objectives:
1. Identify factors impacting outcomes of CD19 CAR-T for large B cell lymphoma
2. Discuss outcomes of a phase 1 trial combining exogenous IL-15 support with CD19 CAR-Ts for large B cell lymphoma
3. Identify insight into the impact of timing of anti-PD-L1 when combined with CD19 CAR-T for large B cell lymphoma
You May Also Like
SEP 30, 2025 | 9:00 AM
Long-read sequencing is transforming the landscape of genomic research, offering exceptional resolution and accuracy in the analysis of complex genetic structures. From research in genetic a...
SEP 30, 2025 | 10:00 AM
Biosafety cabinets (BSCs) are a cornerstone of modern laboratory safety, yet many users lack a clear understanding of how they work, how to use them properly, and how to distinguish between...
OCT 01, 2025 | 1:00 PM
Laboratories are under growing pressure to meet both stringent safety standards and ambitious sustainability goals—often with limited resources. This webinar, hosted by Erlab, a global...
OCT 02, 2025 | 8:00 AM
CAR-T Therapy continues to evolve rapidly, mRNA encoding CAR constructs directly to T cells in the bloodstream, potentially enabling CAR T cell production in the body without the need to iso...
OCT 07, 2025 | 7:00 AM
The analysis of protein behavior and protein interactions is central in drug research. In this web seminar, we will show you how the automation of protein purification and downstream thermal...
OCT 07, 2025 | 7:00 AM
This presentation explores the scientific rationale, preclinical validation, and early clinical translation of STAR-LLD—a novel, continuous low-dose percutaneous lenalidomide delivery...
Loading Comments...